Bayer's Sunharbo Brings a New Approach to Stroke Prevention

Stroke prevention remains a major challenge even after patients survive an initial ischemic stroke or a high-risk transient ischemic attack (TIA).

Many survivors face the risk of another event, which can cause further disability or threaten their lives.

Existing blood thinners target established clotting pathways, but preventing harmful clots without increasing bleeding remains an important treatment challenge.

Bayer’s Sunharbo (asundexian), approved by the US Food and Drug Administration, introduces a different approach.

As the first Factor XIa inhibitor approved in the United States, the medicine brings a new clotting target into secondary stroke prevention and offers an additional option for patients vulnerable to another stroke.

Bayer’s Sunharbo Targets a Different Clotting Pathway

Sunharbo works by blocking Factor XIa, a protein involved in the formation and growth of harmful blood clots. Established blood thinners such as Eliquis and Xarelto target Factor Xa, another protein in the clotting process. Sunharbo instead focuses on Factor XIa, which plays a different role in clot formation.

This distinction matters because Factor XIa contributes to harmful clot growth but plays a smaller role in forming the protective clot that seals a wound. By targeting this pathway, Sunharbo aims to reduce dangerous clot formation while preserving the body's ability to control bleeding.

The FDA approved Sunharbo 50 mg tablets for once-daily use alongside antiplatelet therapy in adults with recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk TIA. This approval introduces a new treatment mechanism rather than another medicine targeting the same established pathway.

Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding

Clinical Results Put Repeat Stroke Prevention in Focus

The FDA approval rests on findings from the Phase III OCEANIC-STROKE trial, which enrolled 12,327 participants. Researchers compared Sunharbo with placebo, with both groups receiving antiplatelet therapy.

The study demonstrated a 26% reduction in ischemic stroke risk with Sunharbo. The results highlight its potential to address the persistent risk of another stroke among patients receiving standard treatment.

Key clinical findings include:

• Lower stroke incidence: 6.2% of participants receiving Sunharbo experienced an ischemic stroke, compared with 8.4% in the placebo group.
• Comparable overall major bleeding: Researchers observed similar overall rates of major bleeding between the treatment and placebo groups.
• Important safety considerations: The FDA reported increased major bleeding among patients older than 75 and during the first 90 days of treatment. Gastrointestinal bleeding also occurred more frequently with Sunharbo.

These findings strengthen the case for a different approach to stroke prevention, although the bleeding concerns underline the importance of careful patient selection and monitoring.

Sunharbo's approval marks an important development in secondary stroke prevention. Its clinical value will depend on how healthcare professionals balance its potential to prevent another stroke against individual bleeding risks and treatment needs.